Crescent Biopharma (CBIO) insider McNeill receives RSUs and stock options

Rhea-AI Filing Summary

Crescent Biopharma, Inc. reported an insider equity grant for its President and COO, Jonathan McNeill. On December 15, 2025, he acquired 19,507 and 6,000 Ordinary Shares as awards of restricted stock units (RSUs), and now directly beneficially owns 159,707 Ordinary Shares.

The RSUs each represent a right to receive one Ordinary Share and will vest in approximately equal three-month installments over four years from December 15, 2025, contingent on continued service. He also received a stock option for 78,029 Ordinary Shares at an exercise price of $13.21 per share, expiring on December 15, 2035. This option vests as to 1/48th of the grant on each monthly anniversary of December 15, 2025, subject to continued employment or service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McNeill Jonathan

(Last) (First) (Middle)

C/O CRESCENT BIOPHARMA, INC.

300 FIFTH AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRESCENT BIOPHARMA, INC. [ CBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	12/15/2025		A		19,507	A	(1)	153,707	D
Ordinary Shares	12/15/2025		A		6,000	A	(1)	159,707	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.21	12/15/2025		A		78,029		(2)	12/15/2035	Ordinary Shares	78,029	$0	78,029	D

Explanation of Responses:

1. Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date.

2. This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date.

Remarks:

	/s/ Barbara Bispham, as attorney-in-fact for Jonathan McNeill	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Crescent Biopharma (CBIO) report for Jonathan McNeill?

Crescent Biopharma reported that President and COO Jonathan McNeill received awards of 19,507 and 6,000 RSU-based Ordinary Shares on December 15, 2025, and a stock option for 78,029 Ordinary Shares at an exercise price of $13.21 per share.

How many Crescent Biopharma (CBIO) shares does Jonathan McNeill beneficially own after this filing?

After the reported transactions, Jonathan McNeill beneficially owns 159,707 Ordinary Shares of Crescent Biopharma directly, according to the filing.

What are the vesting terms of the RSUs granted to Crescent Biopharma (CBIO) executive Jonathan McNeill?

The RSUs granted to Jonathan McNeill vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to his continued employment or service with Crescent Biopharma or its subsidiaries.

What are the key terms of Jonathan McNeill’s Crescent Biopharma (CBIO) stock option grant?

The filing shows a stock option for 78,029 Ordinary Shares with an exercise price of $13.21 per share, expiring on December 15, 2035. The option vests as to 1/48th of the grant on each monthly anniversary of December 15, 2025, contingent on continued service.

What role does the reporting person hold at Crescent Biopharma (CBIO)?

The reporting person in this filing, Jonathan McNeill, is identified as an Officer of Crescent Biopharma, serving as President and COO.

Is this Crescent Biopharma (CBIO) Form 4 filed for an individual or multiple reporting persons?

The document indicates that it is a Form filed by one reporting person, specifically Jonathan McNeill.